Buy Drugs Online:
Drugs Information:
Drugs List

1. Name Of The Medicinal Product

Sectral 400mg Tablets

2. Qualitative And Quantitative Composition

Each tablet contains 443.40mg of the active substance Acebutolol hydrochloride (equivalent to 400mg of base).

Also contains 21.20mg of lactose monohydrate.

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Tablet

White to off-white, circular, biconvex, film-coated tablets with bevel edges, one face impressed 'SECTRAL 400 or ACB 400. Plain reverse.

4. Clinical Particulars

4.1 Therapeutic Indications

The management of hypertension, angina pectoris and the control of tachyarrhythmias.

4.2 Posology And Method Of Administration

Hypertension: Initial dosage of 400mg orally once daily at breakfast or 200mg orally twice daily. If response is not adequate within two weeks, dosage may be increased up to 400mg orally twice daily; in some patients 1200mg orally daily, given as 800mg at breakfast and 400mg in the evening may be required. A further reduction in blood pressure may be obtained by the concurrent administration of a thiazide diuretic or other anti-hypertensive agent (except Rauwolfia and its alkaloids).

Angina pectoris: Initial dosage of 400mg orally once daily at breakfast or 200mg twice daily. In severe forms up to 300mg three times daily may be required. Up to 1200mg daily has been used.

Cardiac Arrhythmias: When given orally, an initial dose of 200mg is recommended. The daily dose requirement for long term anti arrhythmic activity should lie between 400 and 1200mg daily. The dose can be gauged by response, and better control may be achieved by divided doses rather than single doses. It may take up to three hours for maxima

1. Name Of The Medicinal Product

SINGULAIR® Paediatric 5 mg Chewable Tablets

2. Qualitative And Quantitative Composition

One chewable tablet contains montelukast sodium, which is equivalent to 5 mg montelukast.

Excipient: Aspartame (E 951) 1.5 mg per tablet.

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Chewable tablet.

Pink, round, biconvex, diameter 9.5 mm, with 'SINGULAIR' engraved on one side and 'MSD 275' on the other.

4. Clinical Particulars

4.1 Therapeutic Indications

SINGULAIR is indicated in the treatment of asthma as add-on therapy in those patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom “as-needed” short-acting ?-agonists provide inadequate clinical control of asthma.

SINGULAIR may also be an alternative treatment option to low-dose inhaled corticosteroids for patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids (see section 4.2).

SINGULAIR is also indicated in the prophylaxis of asthma in which the predominant component is exercise-induced bronchoconstriction.

4.2 Posology And Method Of Administration

The dosage for paediatric patients 6-14 years of age is one 5 mg chewable tablet daily to be taken in the evening. If taken in connection with food, SINGULAIR should be taken 1 hour before or 2 hours after food. No dosage adjustment within this age group is necessary.

General recommendations:

The therapeutic effect of SINGULAIR on parameters of asth

1. Name Of The Medicinal Product

STILNOCT 10mg

2. Qualitative And Quantitative Composition

Stilnoct 10mg Tablets:

White to off-white film-coated oblong tablet, scored and engraved SN 10 on one side, containing 10mg zolpidem tartrate.

3. Pharmaceutical Form

Coated tablets for oral administration.

4. Clinical Particulars

4.1 Therapeutic Indications

The short-term treatment of insomnia in situations where the insomnia is debilitating or is causing severe distress for the patient.

4.2 Posology And Method Of Administration

Route of administration: Oral

Zolpidem tartrate acts rapidly and therefore should be taken immediately before retiring, or in bed.

The recommended daily dose for adults is 10 mg.

The duration of treatment should usually vary from a few days to two weeks with a maximum of four weeks including tapering off where clinically appropriate.

As with all hypnotics, long-term use is not recommended and a course of treatment should not exceed four weeks.

Special Populations

Children

Safety and effectiveness of zolpidem in paediatric patients under the age of 18 years have not been established. Therefore, zolpidem should not be prescribed in this population (see Section 4.4 Special warnings and precautions for use).

Elderly

Elderly or debilitated patients may be especially sensitive to the effects of zolpidem tartrate therefore a 5mg dose is recommended. These recommended doses should not be exceeded.

Hepatic impairment

As clearance and metabolism of zolpidem tartrate is reduced in hepatic impairment, dosage should begin at 5mg in these patients

SINGULAIR 10 mg film-coated tablets

montelukast

Read all of this leaflet carefully before you start taking this medicine.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, please ask your doctor or pharmacist.
  • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
  • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

In this leaflet:

1. What SINGULAIR is and what it is used for
2. Before you take SINGULAIR
3. How to take SINGULAIR
4. Possible side effects
5. How to store SINGULAIR
6. Further information

What SINGULAIR is and what it is used for

SINGULAIR is a leukotriene receptor antagonist that blocks substances called leukotrienes.

Leukotrienes cause narrowing and swelling of airways in the lungs and also cause allergy symptoms.

By blocking leukotrienes, SINGULAIR improves asthma symptoms, helps control asthma and improves seasonal allergy symptoms (also known as hay fever or seasonal allergic rhinitis).

Your doctor has prescribed SINGULAIR to treat asthma, preventing your asthma symptoms during the day and night.

  • SINGULAIR is used for the treatment of patients who are not adequately controlled on their medication and need additional therapy.
  • SINGULAIR also helps prevent the narrowing of airways triggered by exercise.
  • In those asthmatic patients in whom SINGULAIR is indicated in asthma, SINGULAIR can also provide symptomatic re

1. Name Of The Medicinal Product

Senokot 7.5 mg/5 ml Syrup.

2. Qualitative And Quantitative Composition

Each 5 ml of Senokot Syrup contains calcium sennosides equivalent to 7.5 mg per 5 ml total sennosides (calculated as sennoside B).

3. Pharmaceutical Form

Syrup.

Amber, slightly viscous liquid.

4. Clinical Particulars

4.1 Therapeutic Indications

As a laxative for the relief of occasional or non-persistent constipation.

4.2 Posology And Method Of Administration

Senokot 7.5 mg/5 ml Syrup is for oral administration.

Adults, including the elderly and children over 12: Two 5 ml spoonfuls.

Not to be given to children under 12 years except on medical advice. Where administration to children is necessary, the recommended dose is as follows.

Children over 6 years: One 5 ml spoonful.

Children aged 2 to 6 years: Half to one 5 ml spoonful in 24 hours.

Senokot should be taken as a single dose at bedtime by adults and in the morning by children.

New users should start with the lowest dose and increase it, if necessary, by one half of the initial dose each day. Once regularity has been regained the dosage should be gradually reduced and stopped.

4.3 Contraindications

Senokot 7.5 mg/5 ml Syrup should not be given when any undiagnosed acute or persistent abdominal symptoms are present.

4.4 Special Warnings And Precautions For Use

Not to be given to children except on medical advice.

If there is no bowel movement after three days consult a doctor.

If laxatives are needed every day or abdominal pain persists consult a doctor.

E

1. Name Of The Medicinal Product

Sodium Valproate 200mg Gastro-resistant Tablets

2. Qualitative And Quantitative Composition

Sodium Valproate 200mg.

3. Pharmaceutical Form

Gastro-resistant Tablet.

4. Clinical Particulars

4.1 Therapeutic Indications

In the treatment of generalised, partial or other epilepsy.

4.2 Posology And Method Of Administration

Sodium Valproate 200mgGastro-resistant Tablets are for oral administration.

Daily dosage requirements vary according to age and body weight.

Sodium valproate tablets may be given twice daily. The tablets should be swallowed whole and not crushed or chewed.

Dosage

Usual requirements are as follows:

Adults

Dosage should start at 600mg daily increasing by 200mg at three day intervals until control is achieved. This is generally within the dosage range 1000mg to 2000mg per day, ie 20-30mg/kg/day body weight. Where adequate control is not achieved within this range the dose may be further increased to 2500mg per day.

Children over 20kg

Initial dosage should be 400mg/day (irrespective of weight) with spaced increases until control is achieved; this is usually within the range 20-30mg/kg body weight per day. Where adequate control is not achieved within this range the dose may be increased to 35mg/kg body weight per day.

Children under 20kg

20mg/kg of body weight per day; in severe cases this may be increased but only in patients in whom plasma valproic acid levels can be monitored. Above 40mg/kg/day, clinical che

1. Name Of The Medicinal Product

Strepsils Extra Blackcurrant Lozenges

STREPSILS Extra Triple Action Blackcurrant Lozenges

STREPSILS Extra Strength Blackcurrant Lozenges

2. Qualitative And Quantitative Composition

Each lozenge contains Hexylresorcinol 2.4 mg.

For excipients see Section 6.1.

3. Pharmaceutical Form

Lozenge

A round purple lozenge.

4. Clinical Particulars

4.1 Therapeutic Indications

As an antiseptic and local anaesthetic for the relief of sore throat and its associated pain.

4.2 Posology And Method Of Administration

For oral administration.

Adults, the elderly and children 6 years and over: One lozenge dissolved slowly in the mouth every three hours or as required.

Do not take more than 12 lozenges in 24 hours

Not to be given to children under 6 years.

4.3 Contraindications

Hypersensitivity to any of the ingredients.

4.4 Special Warnings And Precautions For Use

The label will convey

Keep out of reach and sight of children.

If symptoms persist consult your doctor.

Not to be given to children under 6 years.

This product is unsuitable in hereditary fructose intolerance, glucose-galactose malabsorption syndrome, or sucrose-isomaltose deficiency.

4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction

None known.

4.6 Pregnancy And Lactation

There is lack of evidence of safety of the product in human pregnancy and in animals, but hexylresorcinol has been used widely in lozenges for many years wi

1. Name Of The Medicinal Product

Stalevo 125 mg/31.25 mg/200 mg film-coated tablets

2. Qualitative And Quantitative Composition

Each tablet contains 125 mg of levodopa, 31.25 mg of carbidopa and 200 mg of entacapone.

Excipient: Each tablet contains 1.6 mg of sucrose.

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Film-coated tablet

Light brownish red, oval film-coated tablets marked with 'LCE 125' on one side.

4. Clinical Particulars

4.1 Therapeutic Indications

Stalevo is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.

4.2 Posology And Method Of Administration

Each tablet is to be taken orally either with or without food (see section 5.2). One tablet contains one treatment dose and the tablet may only be administered as whole tablets.

The optimum daily dose must be determined by careful titration of levodopa in each patient. The daily dose should be preferably optimised using one of the six available tablet strengths (50 mg/12.5 mg/200 mg, 75 mg/18.75 mg/200 mg, 100 mg/25 mg/200 mg, 125 mg/31.25 mg/200 mg, 150 mg/37.5 mg/200 mg or 200 mg/50 mg/200 mg levodopa/carbidopa/entacapone).

Patients should be instructed to take only one Stalevo tablet per dose administration. Patients receiving less than 70-100 mg carbidopa a day are more likely to experience nausea and vomiting. While the experience with total daily dose greater than 200 mg carbidopa is limited, the maximum recommended daily dose of entacapone is 2,000 mg and therefore the maximum dose is 10 tablets per day for the Stalevo strengths of 50 mg/12.5 mg/200

1. Name Of The Medicinal Product

SINGULAIR Paediatric 4 mg Granules

2. Qualitative And Quantitative Composition

One sachet of granules contains montelukast sodium, which is equivalent to 4 mg montelukast. For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Granules.

White granules

4. Clinical Particulars

4.1 Therapeutic Indications

SINGULAIR is indicated in the treatment of asthma as add-on therapy in those 6 months to 5 year old patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom “as-needed” short acting ?-agonists provide inadequate clinical control of asthma.

SINGULAIR may also be an alternative treatment option to low-dose inhaled corticosteroids for 2 to 5 year old patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids (see section 4.2).

SINGULAIR is also indicated in the prophylaxis of asthma from 2 years of age and older in which the predominant component is exercise-induced bronchoconstriction.

4.2 Posology And Method Of Administration

This medicinal product is to be given to a child under adult supervision. The dosage for paediatric patients 6 months to 5 years of age is one sachet of 4 mg granules daily to be taken in the evening. No dosage adjustment within this age group is necessary. Efficacy data from clinical trials in paediatric patients 6 months to 2 years of age with persistent asthma are limited. Patients should be evaluated after 2 to 4 weeks for response to montelukast treatment. Treatment should be discontinued if a lack of resp

1. Name Of The Medicinal Product

Slow-K® Tablets 600mg

2. Qualitative And Quantitative Composition

Potassium chloride 600mg PhEur

Excipients: also includes sucrose.

For a full list of excipients see 6.1.

3. Pharmaceutical Form

Pale orange, round, biconvex, sugar-coated modified release tablets.

4. Clinical Particulars

4.1 Therapeutic Indications

The correction and/or prevention of hypokalaemia in those patients who cannot tolerate and/or refuse to take liquid or effervescent potassium chloride, or when there is a problem of compliance with these preparations.

4.2 Posology And Method Of Administration

Slow-K is taken orally. It is important that the tablets should be swallowed whole, with fluid, during meals, whilst the patient is sitting upright.

Adults:

The dosage of Slow-K should be adapted to the cause, degree and duration of potassium depletion. 2 to 3 tablets daily are usually an adequate supplement. In states of severe potassium deficiency, a higher dose of 9 to 12 tablets daily may be needed.

If the dosage exceeds 16mmol K+ (2 tablets) it should be taken in divided doses. Where intermittent diuretic therapy is being used, it is advisable to give Slow-K on intervening days between administration of the diuretic. The response to treatment should preferably be monitored by repeat determination of plasma potassium and Slow-K continued until the hypokalaemia has been corrected.

Children: Not recommended.

Elderly: No special dosage regime is usually necessary, but concurrent renal insufficiency should be taken into account (See Section 4.4 “Special warnings and precau

1. Name Of The Medicinal Product

SPIRIVA® 18 microgram, inhalation powder, hard capsule

2. Qualitative And Quantitative Composition

Each capsule contains 22.5 microgram tiotropium bromide monohydrate equivalent to 18 microgram tiotropium.

The delivered dose (the dose that leaves the mouthpiece of the HandiHaler® device) is 10 microgram tiotropium.

Excipient: Lactose monohydrate

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Inhalation powder, hard capsule.

Light green hard capsules with the product code TI 01 and company logo printed on the capsule.

4. Clinical Particulars

4.1 Therapeutic Indications

Tiotropium is indicated as a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD).

4.2 Posology And Method Of Administration

The recommended dosage of tiotropium bromide is inhalation of the contents of one capsule once daily with the HandiHaler device at the same time of day.

The recommended dose should not be exceeded.

Tiotropium bromide capsules must not be swallowed.

Tiotropium bromide should only be inhaled with the HandiHaler device.

Instructions for handling and use:

 

Remember to carefully follow your doctor's instructions for using SPIRIVA. The HandiHaler is especially designed for SPIRIVA. You must not use it to take any other medication. You can use your HandiHal

1. Name Of The Medicinal Product

SPASMONAL Forte 120 mg, Hard capsules.

2. Qualitative And Quantitative Composition

Each capsule contains 120 mg alverine citrate.

3. Pharmaceutical Form

An opaque, size 1 capsule with a grey cap and blue body, marked “SP120”.

4. Clinical Particulars

4.1 Therapeutic Indications

The relief of smooth muscle spasm in conditions such as irritable bowel syndrome, painful diverticular disease of the colon and primary dysmenorrhoea.

4.2 Posology And Method Of Administration

Recommended dose and dosage schedules:

Adults (including the elderly): 1 capsule one to three times daily.

Children below the age of 12 years: Not recommended.

4.3 Contraindications

Paralytic ileus or known hypersensitivity to any of the ingredients.

4.4 Special Warnings And Precautions For Use

Additional warnings to be included in the Patient Information Leaflet:

If this is the first time you have had these symptoms, consult your doctor before using any treatment.

If any of the following apply do not use SPASMONAL Forte 120 mg, it may not be the right treatment for you. See your doctor as soon as possible if:

- you are aged 40 years or over

- you have passed blood from the bowel

- you are feeling sick or vomiting

- you have lost your appetite or lost weight

- you are looking pale and feeling tired

- you are suffering from severe constipation

- you have a fever

- you have recently travelled abroad

- y

1. Name Of The Medicinal Product

Sevredol®tablets 10 mg , 20 mg, 50 mg.

2. Qualitative And Quantitative Composition

Morphine Sulphate 10 mg, 20 mg, 50 mg

For excipients see 6.1.

3. Pharmaceutical Form

Film-coated tablet.

10 mg

Blue, film-coated, capsule-shaped, biconvex tablet with a score line on one side. "IR" is marked on the left side and "10" on the right.

20 mg

Pink, film-coated, capsule-shaped, biconvex tablet with a score line on one side. "IR" is marked on the left side and "20" on the right.

50 mg

Pale, green film-coated, capsule-shaped, biconvex tablet with a score line on one side. "IR" is marked on the left side and "50" on the right.

4. Clinical Particulars

4.1 Therapeutic Indications

Sevredol tablets are indicated for the relief of severe pain.

4.2 Posology And Method Of Administration

Route of administration

Oral.

Adults and children over 12 years.

The dosage of Sevredol tablets is dependent on the severity of pain and the patient's previous history of analgesic requirements. One tablet to be taken every four hours or as directed by a physician. Increasing severity of pain or tolerance to morphine will require increased dosage of Sevredol tablets using 10 mg, 20 mg or 50 mg alone or in combination to achieve the desired relief.

Patients receiving

1. Name Of The Medicinal Product

Strepsils Strawberry Sugar Free Lozenges

2. Qualitative And Quantitative Composition

Amylmetacresol BP 0.6mg/lozenge

2,4-Dichlorobenzyl alcohol 1.2mg/lozenge

For excipients, see 6.1

3. Pharmaceutical Form

Lozenge

4. Clinical Particulars

4.1 Therapeutic Indications

As an antiseptic for the relief of sore throat and its associated pain.

4.2 Posology And Method Of Administration

For oral administration

Adults and children (over 6 years old)

One lozenge to be dissolved slowly in the mouth every 2-3 hours up to a maximum of 12 lozenges in 24 hours.

Not suitable for children under 6 years.

Elderly

There is no need for dosage reduction in the elderly

4.3 Contraindications

Strepsils Strawberry Sugar Free Lozenges are contraindicated in persons who have previously shown hypersensitivity to any of the ingredients.

4.4 Special Warnings And Precautions For Use

Keep all medicines out of the reach and sight of children.

Not to be given to children under 6 years.

If symptoms persist consult your doctor.

Warning: Do not exceed the stated dose.

Consult your doctor if symptoms persist or are accompanied by a high fever or headache.

Contains isomaltitol and maltitol syrup, which may have a mild laxative effect if several are taken a day. Patients with rare hereditary problems of fructose intolerance should not take this medicine.

4.5 Interaction With Other Medicinal Products A

Silkis 3 micrograms/g

c a l c i t r i o l

O I N T M E N T

Read all of this leaflet carefully before you start using this medicine.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
  • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

In this leaflet:

1. What Silkis is and what it is used for
2. Before you use Silkis
3. How to use Silkis
4. Possible side effects
5. How to store Silkis
6. Further information

What Silkis Is And What It Is Used For

Silkis is used for the topical treatment of mild to moderately severe plaque psoriasis with up to one third of body surface area involvement.

It contains an active ingredient, calcitriol (a vitamin D derivate), which inhibits and normalizes the unrestrained cell growth in psoriasis affected skin.

Before You Use Silkis

Do not use Silkis:

  • if you are hypersensitive (allergic) to calcitriol or to any of the other ingredients of Silkis
  • if you are treated by systemic (oral) route for a calcium deficiency
  • if you have high blood calcium levels or if you suffer from abnormal calcium metabolism
  • if you have a kidney or liver disease

Salofalk 1.5g

gastro-resistant prolonged release granules

mesalazine

Read all of this leaflet carefully before you start taking this medicine.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
  • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

In this leaflet:

1. What Salofalk 1.5g granules are and what they are used for
2. Before you take Salofalk 1.5g granules
3. How to take Salofalk 1.5g granules
4. Possible side effects
5. How to store Salofalk 1.5g granules
6. Further information

WHAT SALOFALK 1.5g GRANULES ARE AND WHAT THEY ARE USED FOR

Salofalk granules contain the active substance mesalazine, an anti-inflammatory agent used to treat inflammatory bowel disease.

Salofalk 1.5g granules are used for:

  • the treatment of acute episodes of an inflammatory disease of the large intestine (colon), known by doctors as ulcerative colitis.

BEFORE YOU TAKE SALOFALK 1.5g GRANULES

Do not take Salofalk granules

  • If you are or have been told you are allergic (hypersensitive) to salicylic acid, to salicylates such as Aspirin

1. Name Of The Medicinal Product

Solpadeine Plus Tablets

2. Qualitative And Quantitative Composition

Each tablet contains Paracetamol Ph Eur 500 mg, Codeine Phosphate Hemihydrate Ph Eur 8 mg and Caffeine Ph Eur 30.0 mg.

3. Pharmaceutical Form

Tablet

4. Clinical Particulars

4.1 Therapeutic Indications

For the short term treatment of acute moderate pain which is not relieved by paracetamol, ibuprofen or aspirin alone.

Solpadeine Plus Tablets are recommended for the relief of migraine, headache, backache, rheumatic pain, period pains and dental pain.

4.2 Posology And Method Of Administration

Adults (including the elderly)

2 tablets up to 3 or 4 times a day if necessary. The dose should not be repeated more frequently than every four hours, and not more than 4 doses should be given in any 24 hour period. Do not take for more than 3 days without consulting a doctor.

Children

Not to be given to children under 12 years of age.

For oral administration only.

Do not take for more than 3 days continiously without medical review.

4.3 Contraindications

Hypersensitivity to paracetamol, caffeine, codeine, opioid analgesics or any of the other constituents.

Use of codeine containing products is contraindicated in mothers who are breast feeding unless prescribed by a doctor.

4.4 Special Warnings And Precautions For Use

Care is advised in the administration of paracetamol to patients with renal or hepatic impairment. The hazard of overdose is greater in those with non-cirrhotic alcoholic liver disease.

1. Name Of The Medicinal Product

Sterile Saline Solution (0.9%)

2. Qualitative And Quantitative Composition

None

3. Pharmaceutical Form

Diluent containing sterile solution for the reconstitution of lyophilised vaccine preparations.

4. Clinical Particulars

4.1 Therapeutic Indications

For reconstitution of lyophilised vaccines.

4.2 Posology And Method Of Administration

Subcutaneous or intramuscular injection.

4.3 Contraindications

As for the product to be reconstituted.

4.4 Special Warnings And Precautions For Use

As for the product to be reconstituted.

4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction

As for the product to be reconstituted.

4.6 Pregnancy And Lactation

As for the product to be reconstituted.

4.7 Effects On Ability To Drive And Use Machines

As for the product to be reconstituted.

4.8 Undesirable Effects

As for the product to be reconstituted.

4.9 Overdose

As for the product to be reconstituted.

5. Pharmacological Properties

5.1 Pharmacodynamic Properties

Not applicable.

5.2 Pharmacokinetic Properties

Not applicable.

5.3 Preclinical Safety Data

Not applicable.

6. Pharmaceutical Particulars

6.1 List Of Excipients

Sodium Chloride

Water for Injection

6.2 Incompatibilities

As for the product to be reconstituted.

6.3

1. Name Of The Medicinal Product

SereventTM DiskhalerTM

2. Qualitative And Quantitative Composition

Disks comprising four regularly spaced double-foil blisters each delivering a mixture of 50 micrograms salmeterol (as xinafoate) and lactose used in a Diskhaler device.

For excipients, see section 6.1

3. Pharmaceutical Form

Inhalation powder.

4. Clinical Particulars

4.1 Therapeutic Indications

Salmeterol is a selective ?2-agonist indicated for reversible airways obstruction in patients with asthma and chronic obstructive pulmonary disease (COPD).

In asthma (including nocturnal asthma and exercise induced symptoms) it is indicated for those treated with inhaled corticosteroids who require a long-acting beta agonist in accordance with current treatment guidelines.

Serevent Diskhaler is not a replacement for inhaled or oral corticosteroids which should be continued at the same dose, and not stopped or reduced, when treatment with Serevent Diskhaler is initiated.

4.2 Posology And Method Of Administration

Serevent Diskhaler is for inhalation use only.

Serevent Diskhaler should be used regularly. The full benefits of treatment will be apparent after several doses of the drug.

In reversible airways obstruction such as asthma

Adults (including the elderly): One blister (50 micrograms) twice daily, increasing to two blisters (2 x 50 micrograms) twice daily if required.

Children 4 years and over: One blister (50 micrograms) twice daily.

The dosage or frequency of administration should only be increased on medical advice.

There are insufficient clinical data to recommend the use of Serevent

1. Name Of The Medicinal Product

Sulfasalazine 250mg/5ml Oral Suspension

2. Qualitative And Quantitative Composition

Sulfasalazine 250mg/5ml

3. Pharmaceutical Form

Oral Suspension

4. Clinical Particulars

4.1 Therapeutic Indications

Induction and maintenance of remission of ulcerative colitis and treatment of active Crohn's disease.

4.2 Posology And Method Of Administration

The dose is adjusted according to the severity of the disease and the patient's tolerance of the drug, as detailed below.

A) Ulcerative Colitis

Adults and the Elderly

Severe attacks: 20 to 40 ml four times a day may be given in conjunction with steroids as part of an intensive management regime. Rapid passage of the suspension may reduce the effect of the drug.

The night time interval between doses should not exceed 8 hours.

Moderate attacks: 20 ml four times a day may be taken with or without steroids.

Maintenance therapy: With induction of remission, reduce the dose gradually to 40 ml per day. This dosage should be continued indefinitely, since discontinuance even several years after an acute attack is associated with a four-fold increase in relapse.

Children

The dose is reduced in proportion to body weight.

Acute attack or relapse: 0.8 - 1.2 ml/kg/day.

Maintenance dosage: 0.4 - 0.6 ml/kg/day.

B) Crohn's Disease

In active Crohn's Disease, sulfasalazine should be administered as in attacks of ulcerative colitis (see above).